Table 3.
Duration of antiviral therapy and suppressive regimen for congenital and perinatal or postnatally acquired viral infections
| Conditions | Duration & Comments |
|---|---|
| HSV: central nervous system or disseminated disease | Acyclovir IV for 21 d, continue treatment until repeat cerebrospinal fluid HSV PCR negative |
| HSV: skin, eye, or mouth disease | Acyclovir IV for 14 d |
| HSV suppressive regimen after IV therapy | Acyclovir po for 6 mo, monitor for neutropenia |
| Congenital CMV disease | Valganciclovir po for 6 mo |
| Perinatally or postnatally acquired CMV disease associated encephalitis, hepatitis, pneumonitis, or persistent thrombocytopenia | Ganciclovir IV for 14–21 d, monitor for relapse after treatment completion |
| Influenza A and B viruses therapy | Oseltamivir po for 5 d |
| Influenza A and B viruses prophylaxis | Generally not recommended because of limited safety and efficacy data, discuss with pediatric infectious disease specialist |